Posted in Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotech, Celgene, Daiichi Sankyo, FDA, Forest Labs, GSK, Genentech, J&J, Johnson and Johnson, Lilly, Medical Devices, Medicine, Merck, Novartis, Pfizer, Pharma, Pharma News, Pharmaceutical, Red Cross, Sales training, Sanofi-Aventis, Statins, Takeda, tagged alimta, asco, Avastin, herceptin, Millennium, psoriasis, rad001, ranbaxy, s, trasylol, vaptan, vectibix, viagra, xience, zometa on May 16, 2008 | No Comments »
There’s a ton of stuff going on this week, plus we’re in pre-ASCO mode (so lots of oncology news - scroll down for those headlines). Here we go:
What’s a vaptan? Maybe something pretty exciting - A new class of drugs called vaptans may be able to treat a wide variety of conditions including painful periods, [...]
Read Full Post »
Posted in Abbott, Biotech, Cephalon, Healthcare, Medical Devices, Medicine, Merck, Novo Nordisk, Pharma, Pharma News, Pharmaceutical, tagged ADHD, Fentora, King Pharma, Medtronic, NovoSeven on May 12, 2008 | No Comments »
Merck the latest to make major cuts to its sales force - The unwinding of the Big Pharma sales armies continues apace, with Merck saying late today that it’s cutting its U.S. sales force by 1,200 positions, or about 14% from 8,500 reps at the start of 2007…more (and, in a strange twist, it appears [...]
Read Full Post »
Posted in Biotech, J&J, Johnson and Johnson, Medicine, Merck, Pfizer, Takeda, Wyeth, tagged amitiza, Centocor, IBS-C, ortho biotech, Progenics on May 2, 2008 | No Comments »
BMS to sell off ConvaTec - Drug developer Bristol-Myers Squibb Co. said Friday it will sell its would therapy and surgical care unit for $4.1 billion to two private equity firms…more
Big cutback/merger action at J&J - sales and marketing for Ortho Biotech and Centocor to join, 400 jobs to go - Johnson & Johnson yesterday [...]
Read Full Post »
Posted in Biotech, GSK, Glaxosmithkline, Marketing, Medical Devices, Medicine, Pharma, Pharma News, Pharmaceutical, Statins, tagged Chocolate, Zimmer on April 28, 2008 | 1 Comment »
Statin and Alzheimer’s…ummm, maybe not - More news from that big neurology meeting : Lipitor doesn’t help slow cognitive decline in Alzheimer’s patients, researchers said this week. That’s something of a disappointment, given that it was a big, randomized study, and earlier data had showed promise. On the other hand, Alzheimer’s patients who took [...]
Read Full Post »
Posted in Biotech, FDA, Friday Collection, Healthcare, Lilly, Marketing, Medicine, Merck, News, Pharma, Pharma News, Pharmaceutical, Sanofi-Aventis, Schering, Statins, Takeda, Wyeth, tagged Abilify, ACC, angiomax, cialis, Crestor, Humalog, Improve-It, Lantus, lunesta, Otsuka, prasugrel, singulair, vytorin on March 29, 2008 | No Comments »
Breaking news from the ACC:
Vytorin/Zetia gets panned - shows no benefit on the primary endpoint, though effective in reducing some markers. Doctors now wary and skeptical. Merck and Schering-Plough comment. Good summary with more links from Ed Silverman (Pharmlot blog - one of the best btw!) here.
Prasugrel gets a boost - The investigational antiplatelet [...]
Read Full Post »
Posted in AstraZeneca, Bayer, Biotech, Celgene, Cephalon, Daiichi Sankyo, FDA, Forest Labs, GSK, Glaxosmithkline, J&J, Johnson and Johnson, Lilly, Merck, Novartis, Pharma News, Pharmaceutical, Sanofi-Aventis, Schering, tagged alzheimers, Biogen-Idec, Celgene, Eisai, Gleevec, MGI Pharma, Mylan, prasugrel, revlimid, taurel, Treanda, tykerb, Velcade, vytorin, Zevalin on December 18, 2007 | No Comments »
Some interesting oncology results:
Millennium’s Velcade used in combo therapy for multiple myeloma shows impressive results.
Cephalon’s Treanda shows impressive remission numbers for CLL, and effectiveness in non-Hodgins lymphoma (NHL).
Celgene’s Revlimid continues to produce good results at a low-dose regimen.
Novartis‘ Gleevec: effective at halting leukemia progression up to 6 years.
Eisai decides to grab MGI Pharma, and its [...]
Read Full Post »
Posted in Abbott, Biotech, Celgene, GSK, Glaxosmithkline, Healthcare, J&J, Johnson and Johnson, Medical Devices, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, tagged natrecor, par-4, resveratrol, revlimid, sirtris, Tasigna, xience on November 29, 2007 | No Comments »
Glaxo buying Reliant - GlaxoSmithKline Plc has agreed to buy privately held heart drug specialist Reliant Pharmaceuticals for $1.65 billion in cash, in a move to boost its flagging drug sales in the United States…more
J&J says good-bye to $440 mil - Johnson & Johnson said on Thursday its fourth-quarter results would include a special after-tax, [...]
Read Full Post »
Looks, on the surface, like a good match of products and market presence - Celgene buys Pharmion. And, in other important oncology news, Nexavar (from Bayer) gets expedited approval for liver cancer.
Also, Schering cleared to take over Organon - by divesting bird vaccines to Wyeth.
Read Full Post »
Posted in Amylin, Avandia, Bayer, Biotech, GSK, Genentech, Genzyme, Glaxosmithkline, J&J, Johnson and Johnson, Lilly, Medical Devices, Merck, News, Novartis, Pharma, Pharma News, Pharmaceutical, Wyeth, tagged Avandia, Boston Scientific, Byetta, Doribax, Exubera, InVentiv Health, Isentress, Ixempra, Januvia, Lexiva on October 19, 2007 | 2 Comments »
The Good Stuff:
BMS gets approval for new oncology drug (for breast cancer) Ixempra.
Merck gets new HIV drug (Isentress) approved in the U.S. And, their Januvia diabetes drug gets new uses approved.
Abraxis gets cancer drugs approved.
J&J gets Doribax (for intra-abdominal and urinary tract infections) approved.
Bayer reports upbeat MS drug results.
Glaxo: new use of HIV drug Lexiva [...]
Read Full Post »
Posted in Avandia, BMS, Biotech, Daiichi Sankyo, FDA, Forest Labs, Friday Collection, GSK, Glaxosmithkline, Healthcare, J&J, Johnson and Johnson, Marketing, Medical Devices, Novartis, Novo Nordisk, Oncology, Pharma, Pharma News, Pharmaceutical, Wyeth on August 24, 2007 | No Comments »
Novartis gets approval for Reclast, a once-per-year osteoporosis treatment. That’s a game-changer - very cool advance that should lead to far better patient compliance.
A long-ish article on Wyeth’s efforts to find Alzheimer’s treatments. It’s a risky R&D commitment, but nobody questions that desirability of finding new advances here. Also, MedAd News has a brief interview [...]
Read Full Post »
